Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autor principal: | Paul, Pulock |
---|---|
Otros Autores: | Azam,Faruque |
Formato: | Tesis |
Lenguaje: | English |
Publicado: |
Brac University
2024
|
Materias: | |
Acceso en línea: | http://hdl.handle.net/10361/23954 |
Ejemplares similares
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
por: Rahman, Tasnim
Publicado: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
por: Hoque, Ismoth Ara
Publicado: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
por: Karim, Samia Binte
Publicado: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
por: Flora, Sanzida Alam
Publicado: (2024) -
A review on targeted therapies for lung cancer
por: Ashraf, Anushey
Publicado: (2023)